Baxter International (NYSE:BAX) is expected to report Q1 earnings Thursday, April 22 before market open with a conference call scheduled for 8:30am ET.
Analysts are looking for EPS of 93c on revenue of $3.09B. The consensus range is 92c-94c for EPS, and $3.06B-$3.12B for revenue, according to First Call. This quarter's earnings should benefit from sales growth for recombinants and an increase in vaccine sales for H1N1. On January 28, Baxter said it sees Q1 EPS 92c-94c on revenue it expects to be up 5% to 7%. Possible negatives for the quarter include intravenous immunolglobulin, or IVIG, demand fundamentals for 2010.
On March 3, Barrons.com said that Baxter shares offer a compelling opportunity. Barron's cited Baxter's cash flow enabling stock repurchases and dividend hikes.